160 related articles for article (PubMed ID: 24492353)
1. Increased risk of myocardial infarction with dabigatran: fact or fiction?
Giglio AF; Basile E; Santangeli P; Di Biase L; Trotta F; Natale A
J Cardiovasc Med (Hagerstown); 2014 Jan; 15(1):19-26. PubMed ID: 24492353
[TBL] [Abstract][Full Text] [Related]
2. Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
Pontillo D; Patruno N
J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):142. PubMed ID: 25539158
[No Abstract] [Full Text] [Related]
3. Risk of major bleeding and the standard doses of dabigatran.
Antoniazzi S; Berdaï D; Conti V; Clementi E; Salvo F
Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
[No Abstract] [Full Text] [Related]
4. Dabigatran for stroke prevention in atrial fibrillation.
Hohnloser SH; Diener HC
Hamostaseologie; 2012; 32(3):216-20. PubMed ID: 22739760
[TBL] [Abstract][Full Text] [Related]
5. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Clemens A; Fraessdorf M; Friedman J
Vasc Health Risk Manag; 2013; 9():599-615. PubMed ID: 24143109
[TBL] [Abstract][Full Text] [Related]
7. [Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
Tkacheva ON; Akasheva DU
Ter Arkh; 2014; 86(4):103-7. PubMed ID: 24864477
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
Uchino K; Hernandez AV
Arch Intern Med; 2012 Mar; 172(5):397-402. PubMed ID: 22231617
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
[TBL] [Abstract][Full Text] [Related]
10. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Artang R; Rome E; Nielsen JD; Vidaillet HJ
Am J Cardiol; 2013 Dec; 112(12):1973-9. PubMed ID: 24075284
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
16. [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
Beliavskaia OO; Vavilova TV
Angiol Sosud Khir; 2014; 20(4):37-41. PubMed ID: 25490355
[TBL] [Abstract][Full Text] [Related]
17. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
18. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Barrios V; Escobar C
Expert Opin Pharmacother; 2012 Dec; 13(18):2649-61. PubMed ID: 23167273
[TBL] [Abstract][Full Text] [Related]
19. Place of dabigatran in contemporary pharmacotherapy.
Gums JG
Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
[No Abstract] [Full Text] [Related]
20. Dabigatran etexilate: future directions in anticoagulant treatment.
Schulman S; Reilly PA
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
